Antibe Therapeutics Inc. (ATBPF) Income Statement Analysis

See more : Duncan Engineering Limited (DUNCANENG.BO) Income Statement Analysis – Financial Results

Complete financial analysis of Antibe Therapeutics Inc. (ATBPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Antibe Therapeutics Inc., a leading company in the Medical – Devices industry within the Healthcare sector.

You may be interested

Antibe Therapeutics Inc. (ATBPF)

Industry: Medical - Devices

Sector: Healthcare

Website: https://www.antibethera.com

About Antibe Therapeutics Inc.

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	0.00	0.00	9.71M	9.99M	9.54M	8.51M	9.05M	4.44M	19.96K	0.00	0.00	0.00
Cost of Revenue	0.00	99.00K	6.16M	6.10M	5.99M	5.13M	5.12M	2.38M	150.00K	0.00	0.00	0.00
Gross Profit	0.00	-99.00K	3.55M	3.89M	3.55M	3.38M	3.93M	2.06M	-130.04K	0.00	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	36.55%	38.94%	37.21%	39.66%	43.45%	46.34%	-651.62%	0.00%	0.00%	0.00%
Research & Development	11.31M	14.36M	13.43M	8.08M	3.94M	2.74M	700.80K	407.22K	2.30M	1.23M	262.82K	214.14K
General & Administrative	8.91M	10.96M	11.19M	8.77M	7.86M	3.54M	6.55M	3.78M	1.85M	1.34M	755.93K	728.00K
Selling & Marketing	331.00K	208.00K	2.72M	3.79M	3.52M	3.38M	1.54M	202.27K	53.28K	72.24K	10.79K	0.00
SG&A	9.24M	11.17M	13.91M	12.56M	11.38M	6.92M	8.09M	3.99M	1.90M	1.41M	755.93K	728.00K
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	20.55M	25.53M	27.81M	21.21M	15.74M	10.04M	9.14M	5.23M	4.42M	2.67M	1.02M	942.14K
Cost & Expenses	20.55M	25.53M	33.98M	27.30M	21.73M	15.17M	14.26M	7.61M	4.42M	2.67M	1.02M	942.14K
Interest Income	1.35M	282.00K	52.00K	99.00K	31.41K	17.35K	3.64K	6.40K	19.96K	6.30K	0.00	0.00
Interest Expense	8.00K	8.00K	236.00K	500.00K	430.29K	1.18M	835.17K	324.62K	384.00	15.17K	26.36K	0.00
Depreciation & Amortization	99.00K	99.00K	478.00K	571.00K	416.22K	377.14K	352.61K	158.74K	19.96K	21.46K	26.36K	0.00
EBITDA	-20.45M	-25.15M	-23.73M	-17.98M	-11.84M	-6.15M	-4.92M	-2.99M	-4.40M	-2.66M	-1.02M	-942.14K
EBITDA Ratio	0.00%	0.00%	-244.33%	-166.68%	-123.08%	-73.67%	-53.59%	-67.95%	-22,053.26%	0.00%	0.00%	0.00%
Operating Income	-20.55M	-25.53M	-24.71M	-18.92M	-12.19M	-6.66M	-5.21M	-3.28M	-4.42M	-2.69M	-1.05M	-942.14K
Operating Income Ratio	0.00%	0.00%	-254.44%	-189.42%	-127.77%	-78.31%	-57.53%	-73.96%	-22,153.26%	0.00%	0.00%	0.00%
Total Other Income/Expenses	1.26M	279.00K	-1.20M	-1.72M	-494.00K	-1.04M	-902.10K	-347.74K	19.57K	-8.87K	0.00	0.00
Income Before Tax	-19.29M	-25.25M	-24.73M	-19.35M	-12.68M	-7.70M	-6.11M	-3.50M	-4.40M	-2.68M	-1.05M	-942.14K
Income Before Tax Ratio	0.00%	0.00%	-254.65%	-193.74%	-132.95%	-90.53%	-67.49%	-78.80%	-22,053.26%	0.00%	0.00%	0.00%
Income Tax Expense	184.00K	-182.00K	1.80M	-7.00K	134.13K	-274.76K	-365.00K	-865.20K	0.00	0.00	26.36K	0.00
Net Income	-19.48M	-25.06M	-26.30M	-19.34M	-12.82M	-7.43M	-5.75M	-2.63M	-4.40M	-2.68M	-1.05M	-942.14K
Net Income Ratio	0.00%	0.00%	-270.78%	-193.67%	-134.36%	-87.31%	-63.46%	-59.30%	-22,053.26%	0.00%	0.00%	0.00%
EPS	-0.37	-0.49	-0.71	-0.71	-0.60	-0.49	-0.60	-0.42	-1.19	-1.02	-0.40	-0.36
EPS Diluted	-0.37	-0.49	-0.71	-0.71	-0.60	-0.49	-0.60	-0.42	-1.19	-1.02	-0.40	-0.36
Weighted Avg Shares Out	52.29M	50.77M	37.25M	27.27M	21.49M	15.16M	9.57M	6.27M	3.69M	2.62M	2.61M	2.61M
Weighted Avg Shares Out (Dil)	52.29M	50.77M	37.25M	27.27M	21.49M	15.16M	9.57M	6.27M	3.69M	2.62M	2.61M	2.61M

Antibe Reports Q2 2024 Interim Financial and Operating Results

November 13, 2023businesswire.com

TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE REPORTS Q2 2024 INTERIM FINANCIAL AND OPERATING RESULTS.

Antibe Reports PK Results of First Clinical Study of Otenaproxesul's New Formulation

November 9, 2023businesswire.com

TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE REPORTS PK RESULTS OF FIRST CLINICAL STUDY OF OTENAPROXESUL'S NEW FORMULATION.

Antibe Completes First Clinical Study of Otenaproxesul's New Formulation

November 1, 2023businesswire.com

TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE COMPLETES FIRST CLINICAL STUDY OF OTENAPROXESUL'S NEW FORMULATION.

Antibe Initiates First Clinical Study of Otenaproxesul's New Formulation

October 18, 2023businesswire.com

TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE INITIATES FIRST CLINICAL STUDY OF OTENAPROXESUL'S NEW FORMULATION.

Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul

September 28, 2023businesswire.com

TORONTO--(BUSINESS WIRE)---- $ATBPF--Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul.

Antibe Announces Results of 2023 Annual Meeting

September 8, 2023businesswire.com

TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE ANNOUNCES RESULTS OF 2023 ANNUAL MEETING.

Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite

August 21, 2023prnewswire.com

TORONTO , Aug. 21, 2023 /PRNewswire/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview with TMX Group. The View From The C-Suite video interview series highlights the unique perspectives...